GENE ONLINE|News &
The CDMO Crossroads: End-to-End Giants vs. Niche Technical Experts
Industry leaders from EirGenix, TLC BioSciences, Sanofi, AGC Biologics, and AmbioPharm explore emerging CDMO strategies during a panel discussion at BIO Asia-Taiwan 2026. (Source: GeneOnline)
The contract development and manufacturing organization (CDMO) session at BIO Asia-Taiwan 2026 convened global biomanufacturing executives, bioprocess engineers, and biopharma supply chain leaders to analyze strategic operational models driving pharmaceutical outsourcing. The biopharmaceutical industry is undergoing a structural inflection point, driven by the rapid diversification of therapeutic modalities beyond traditional monoclonal antibodies into highly complex … The CDMO Crossroads: End-to-End Giants vs. Niche Technical Experts Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.
GO Prime with only $1.49 now
LATEST
Wendy Short Bartie Repositions Bristol Myers Squibb Corporate Affairs to Integrate Patient Advocacy and Healthcare Access
2026-09-14
Wendy Short Bartie Restructures Bristol Myers Squibb Corporate Affairs to Link Reputation with Business Performance
2026-09-14
Wendy Short Bartie Integrates Patient Advocacy and Public Trust into Bristol Myers Squibb Business Strategy
2026-09-14
Mycenax Teams Up with Global Partners to Expedite R&D and Market Launch of Next-Generation ADCs
2026-09-14
Chinese Bispecific Antibody Tops Keytruda in First Head-to-Head OS Win; SMA Muscle-Strengthening Therapy Approved, B7-H3 ADC Shows Promise
2026-09-14
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
